Liraglutide Injection Shortage: Current Status and Details
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA has reported a current shortage of certain presentations of Liraglutide Injection due to delays in shipping, affecting some brands like Victoza.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action, a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Liraglutide) map to related alerts in the same area of risk - browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What's in Shortage
The generic drug name is Liraglutide Injection. Brand names include VICTOZA, SAXENDA, and LIRAGLUTIDE. The dosage form is Injection, and the current status is ongoing as per the latest FDA data. This medication falls under the therapeutic category of Endocrinology/Metabolism. The shortage was first posted on 07/18/2023 and last updated on 04/01/2026.
Which Manufacturers Are Affected
The affected manufacturer is Novo Nordisk, Inc. Here are the details for each presentation:
- Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13): Limited Availability, with an estimated shortage duration TBD. Contact information: 833-493-4689.
- Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15): Available. Contact information: 833-493-4689.
- Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22): Available, and it is distributed by Teva. Contact information: 833-493-4689.
- Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12): Limited Availability, with an estimated shortage duration TBD. Contact information: 833-493-4689.
- Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20): Available, and it is distributed by Teva. Contact information: 833-493-4689.
Why There's a Shortage
The reason for the shortage is a delay in shipping of the drug. No additional details were provided.
What Patients Should Do
Patients who rely on this medication should speak with their pharmacist to check availability and discuss options. They may also contact the manufacturer directly using the provided contact information. Remember, patients should consult their healthcare provider for any guidance on their treatment; this article does not provide medical advice or suggest specific alternatives.
Source
This information is sourced from the FDA Drug Shortages Database, with the shortage initially posted on 07/18/2023 and last updated on 04/01/2026.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.